IDE849

DRUG2 trials

Sponsors

Ideaya Biosciences Inc., IDEAYA Biosciences

Conditions

DLL3 Expressing Tumors Including Small Cell Lung CancerNeuroendocrine CarcinomasSmall-cell Lung CancerSolid Tumor Show to Express DLL3

Phase 1

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

RecruitingNCT07174583

IDEAYA BiosciencesNeuroendocrine Carcinomas, Small-cell Lung Cancer, Solid Tumor Show to Express DLL3

Start: 2025-10-14End: 2029-07-01Target: 262Updated: 2026-07-09

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer

Not yet recruitingCTIS2025-523438-24-00

Ideaya Biosciences Inc.DLL3 Expressing Tumors Including Small Cell Lung Cancer

Target: 35Updated: 2026-07-03